p53 Immunophenotype and Clinical Features Associated with Endometrial Polyp Recurrence in Women with Metabolic Syndrome: A Retrospective Cohort Study
Journal of Visualized Experiments · 2026
DOI: 10.3791/73553 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Shasha Liu and 7 co-authors. Institution: Emergency Intensive Care Unit, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine. Major MEDLINE topics: Polyps, Tumor Suppressor Protein p53, Metabolic Syndrome, Uterine Diseases.
Abstract (original language)
Endometrial polyp recurrence after hysteroscopic resection remains clinically relevant in women with metabolic syndrome. In this retrospective cohort study, we evaluated the associations of a prespecified study-defined diffuse-strong p53 immunohistochemical phenotype, Ki-67 expression, and selected clinical characteristics with 24-month recurrence and explored the incremental discrimination provided by the IHC markers. The analytic cohort included 180 women with metabolic syndrome (MetS) who underwent hysteroscopic resection of histologically confirmed endometrial polyps (EPs) and had ascertainable recurrence status through 24 months. Associations with recurrence were assessed using a prespecified multivariable logistic model and a supportive multivariable Cox model, while exploratory prediction performance was evaluated using repeated stratified cross-validation. During 24 months of follow-up, 58 of 180 women (32.2%) had documented recurrence. Diffuse-strong p53 phenotype (adjusted odds ratio (aOR) 2.74, 95% CI 1.32-5.68), multiple polyps (aOR 2.74, 95% CI 1.25-6.02), AUB (aOR 2.29, 95% CI 1.12-4.65), and endometrial thickness (aOR 1.25 per mm, 95% CI 1.05-1.48) were independently associated with recurrence. Ki-67 ≥ 10% showed a directionally positive but statistically uncertain adjusted association (aOR 1.85, 95% CI 0.88-3.90). Supportive Cox analysis showed associations of diffuse-strong p53 phenotype, multiple polyps, AUB, and endometrial thickness with time to recurrence, whereas the estimate for Ki-67 remained statistically uncertain. The integrated model showed modestly higher repeated cross-validated discrimination than the clinical-only model (AUC 0.734 vs. 0.679; ΔAUC 0.056, 95% CI 0.006-0.105). Diffuse-strong p53 phenotype and selected clinical characteristics were associated with recurrence, whereas the contribution of Ki-67 remained exploratory; the modest incremental discrimination of the integrated model requires external validation before clinical application.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Emergency Intensive Care Unit, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine.
- Department of Women's Health Care, Ezhou Maternal and Child Health Hospital.
- Department of Gynecology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine.
- Department of Pathology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine.
- Department of Obstetrics, Xianyang Maternal and Child Health Hospital; lihaiying202325@outlook.com.
Cite
APA
Liu, S., Cai, L., Geng, L., Pang, L., Xu, H., Chen, N., Li, X., & Li, H. (2026). p53 Immunophenotype and Clinical Features Associated with Endometrial Polyp Recurrence in Women with Metabolic Syndrome: A Retrospective Cohort Study. Journal of Visualized Experiments. https://doi.org/10.3791/73553
Vancouver
Liu S, Cai L, Geng L, Pang L, Xu H, Chen N, et al. p53 Immunophenotype and Clinical Features Associated with Endometrial Polyp Recurrence in Women with Metabolic Syndrome: A Retrospective Cohort Study. Journal of Visualized Experiments. 2026. doi:10.3791/73553
BibTeX
@article{Liu2026,
author = {Liu, Shasha and Cai, Li and Geng, Lili and Pang, Lanting and Xu, Hua and Chen, Na and Li, Xiaodan and Li, Haiying},
title = {p53 Immunophenotype and Clinical Features Associated with Endometrial Polyp Recurrence in Women with Metabolic Syndrome: A Retrospective Cohort Study},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/73553}
}
EUVIMED